“Prostate Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Prostate Cancer Market.
The Prostate Cancer Pipeline report embraces in-depth commercial, regulatory, and Prostate Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Prostate Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Prostate Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for Prostate Cancer treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Prostate Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Prostate Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Prostate Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Prostate Cancer therapeutic market.
Prostate Cancer Therapeutics Landscape
Active Surveillance is the treatment of choice for patients with very low risk of prostate cancer to reduce or delay the morbidity of radial prostatectomy. However, surgery is a common choice for prostate cancer treatment if the disease has not spread outside the prostate gland. For prostate cancer, radical prostatectomy remains the gold standard for surgical management. Radical prostatectomy (RP) has been demonstrated to improve survival among patients with an intermediate risk of cancer-specific mortality and healthy life expectancy.
Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. At present, immunotherapy has made a major impact on the treatment of metastatic cancer and has altered the standard of care for many tumor types. Immunotherapy has been explored in prostate cancer as single-agent therapy and in combination with other immunotherapies.
There are approx. 200+ key companies developing therapies for Prostate Cancer. Currently, Merck is leading the therapeutics market with its Prostate Cancer drug candidates in the most advanced stage of clinical development.
Prostate Cancer Companies Actively Working in the Therapeutic Market Include:
Advantagene, Advaxis, Inc., Allife Medical Science and Technology, Amgen, Arvinas Inc, Astellas Pharma, AstraZeneca, Bavarian Nordic, Bayer, BeiGene, Blue Earth Diagnostics, Bracco Diagnostics, Inc, Bristol-Myers Squibb, Cancer Targeted Technology, Cardiff Oncology, Clarity Pharmaceuticals, Clovis Oncology, eFFECTOR Therapeutics, Eli Lilly and Company, Emtora Biosciences, Epizyme, ESSA Pharma, Exelixis, Fortis Therapeutics, Inc., Genmab, Genovax, Harpoon Therapeutics, Hinova Pharmaceuticals, Hoffmann-La Roche, Immunomedics, Innocrin Pharmaceutical, Janssen Research & Development, Jiangsu Hengrui Medicine Co., Laekna Limited, Leap Therapeutics, Luye Pharma Group, MacroGenics, Matrix Biomed, Merck & Co, Myovant Sciences/Takeda, Novartis, Nymox Pharmaceutical, Orion Corporation, Pfizer, Plexxikon, Regeneron Pharmaceuticals, RhoVac, Sanofi, Sophiris Bio, Suzhou Kintor Pharmaceutical, Tavanta Therapeutics, Teneobio, Inc., Tracon, Trovagene, Vaccitech, Veru Inc., Zenith Epigenetics, and others.
Emerging and Marketed Prostate Cancer Drugs Covered in the Report Include:
177Lu-PSMA-617: NovartisXtandi (Enzalutamide): Astellas Pharma/Pfizer
EPI-7386: ESSA Pharma
Erleada (apalutamide): Janssen Pharmaceutical
Ipatasertib (RG7440): Hoffmann-La Roche
Keytruda: Merck Sharp & Dohme
Lynparza (olaparib): AstraZeneca/Merck Sharp & Dohme
Nubeqa (Darolutamide/ODM-201): Bayer HealthCare/Orion Corporation
ODM-208: Orion
Pembrolizumab: Merck & Co
ProstAtak: Advantagene
Rubraca (Rucaparib): Clovis Oncology
Talzoparib: Pfizer/Astellas Pharma
ZEN 3694: Zenith Epigenetics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Prostate Cancer Companies Working in the Market @
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
Analysis of Emerging Prostate Cancer Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Learn How the Prostate Cancer Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Prostate Cancer Treatment Patterns
4. Prostate Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Prostate Cancer Late Stage Products (Phase-III)
7. Prostate Cancer Mid-Stage Products (Phase-II)
8. Prostate Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prostate Cancer Discontinued Products
13. Prostate Cancer Product Profiles
14. Major Prostate Cancer Companies in the Market
15. Key Products in the Prostate Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Prostate Cancer Unmet Needs
18. Prostate Cancer Future Perspectives
19. Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Bone Resorption Market
“Bone Resorption Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Bone Resorption market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Bone Resorption market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/medical-devices
